Patient No. | Age | Gender | Marriage | History (year) | Height (cm) | Body weight (kg) | C-peptide (ng/ml)* | Auto-Antibodies | HbA1C (%) | Insulin dose (U/day) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IA-2A | GAD | ICA | IAA | ||||||||||
Group A: Long-standing patients having some residual islet β cell function and received therapy with CB-SC | |||||||||||||
1 | 17 | F | No | 5 | 145 | 35 | 0.30 | - | + | - | - | 12.3 | 52 |
2 | 23 | F | No | 5 | 167 | 59 | 0.56 | - | + | - | - | 6.6 | 50 |
3 | 38 | F | Yes | 11 | 160 | 60 | 0.12 | - | + | - | - | 7.3 | 23 |
4 | 39 | F | Yes | 1 | 156 | 49 | 0.636 | + | + | + | - | 11.3 | 22 |
5 | 31 | M | Yes | 14 | 170 | 70 | 0.18 | + | + | - | - | 6.5 | 30 |
6 | 30 | M | Yes | 2 | 182 | 70 | 0.18 | - | + | - | - | 8.4 | 40 |
Mean (SD) | 30 (9) | 6 (5) | 163 (12.7) | 57 (13.4) | 0.33 (0.22) | 8.7 (2.5) | 36.2 (13.2) | ||||||
Group B: Long-standing severe patients with no residual islet b cell function and received therapy with CB-SC | |||||||||||||
7 | 40 | M | Yes | 17 | 170 | 72.5 | 0.01 | - | + | - | - | 8.8 | 48 |
8 | 15 | F | No | 5 | 163 | 65 | 0.01 | - | + | - | - | 15.5 | 50 |
9 | 21 | F | No | 4 | 168 | 65 | 0.01 | + | - | - | - | 9.9 | 46 |
10 | 23 | F | No | 12 | 162 | 80 | 0.01 | + | + | + | - | 16.5 | 60 |
11 | 40 | F | Yes | 21 | 160 | 67 | 0.01 | + | - | - | - | 8.6 | 37 |
12 | 21 | F | No | 5 | 157 | 56 | 0.01 | - | + | - | - | 13.6 | 50 |
Mean (SD) | 27 (11) | 11 (7) | 163 (4.9) | 67.6 (8.1) | 0.01 (0) | 12.2 (3.5) | 48.5 (7.4) | ||||||
Control group: Long-standing patients having some residual islet β cell function and received sham therapy | |||||||||||||
13 | 35 | M | Yes | 1 | 178 | 73.5 | 0.37 | + | - | + | - | 9.8 | 30 |
14 | 41 | M | Yes | 14 | 165 | 65 | 0.55 | - | + | - | - | 6.4 | 48 |
15 | 24 | M | No | 3 | 175 | 58 | 0.3 | - | + | - | - | 10.7 | 48 |
Mean (SD) | 33 (9) | 6 (7) | 173 (6.8) | 65.5 (7.8) | 0.41 (0.13) | 9.0 (2.3) | 42 (10.4) |